Genmab Reports 36% Revenue Growth in H1 2024
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
- Latest
- Trending
Genmab's H1 2024 results show 36% revenue growth; DARZALEX sales surge, and strategic acquisition of ProfoundBio boosts future potential.
Ulta Beauty shares jump 14% post-Buffett stake. Key price levels: $373, $406, $440, $487. Analyze chart trends.
Bitcoin surges 2.85% to $60,948 as US PPI data boosts hopes of interest rate cuts.
Glanbia reports 12.4% EPS growth in H1 2024 amid strong demand and strategic acquisitions.
Analyst Kevin Svenson predicts a Bitcoin surge as the stock market rebounds, eyeing a potential new all-time high.
Ethereum ETFs attract inflows, face $2,799 resistance. ETH consolidates between $2,000-$2,100 before potential upward move.
Bitcoin's dip below $60K causes market liquidations and cap decline.
Paysafe's revenue beats estimates, shares surge 10% as full-year guidance is raised, boosting investor confidence.
Ethereum set for potential rally with ETF inflows rising and CPI data low, but key trendline poses challenge.
Bitcoin's price struggles below $59K as inflation and economic data loom, with limited institutional demand.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.